Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Phenylalanine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.70 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.70 |
| ▸ | SLC7A5 | Q01650 | 5/20 | 0.81 |
| ▸ | ALPI | P09923 | 1/20 | 0.81 |
| ▸ | PKM | P14618 | 1/20 | 0.81 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.81 |
| ▸ | XIAP | P98170 | 1/20 | 0.81 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.70 |
| ▸ | MAOA | P21397 | 1/20 | 0.70 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.70 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.70 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.70 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.70 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.70 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.59 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.59 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.59 |
| ▸ | NOS3 | P29474 | 2/20 | 0.58 |
| ▸ | NOS1 | P29475 | 2/20 | 0.58 |
| ▸ | NOS2 | P35228 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dl-Phenylalanine SCHEMBL579040 | 1.00 | SLC7A5 (0.81) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL14233567 | 0.92 | SLC7A5 (0.69) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL28229442 | 0.91 | SLC7A5 (0.85) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL2063249 | 0.91 | SLC7A5 (0.85) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL9226754 | 0.91 | SLC7A5 (0.85) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL3486837 | 0.91 | SLC7A5 (0.85) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL37367 | 0.91 | SLC7A5 (0.85) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL6033327 | 0.91 | SLC7A5 (0.85) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL6535507 | 0.91 | SLC7A5 (0.85) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL8910300 | 0.91 | SLC7A5 (0.85) | SLC7A5ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644019-B2 | ABUSE RESISTANT AMPHETAMINE COMPOUNDS | SHIRE LLC (US) | 2018-02-21 | — | — | EP | disclosed |
| CN-1816346-B | Abuse resistant amphetamine compounds | SHIRE LLC | 2013-04-17 | — | — | CN | disclosed |
| US-20120115950-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2012-05-10 | — | — | US | disclosed |
| EP-1644019-B1 | ABUSE RESISTANT AMPHETAMINE COMPOUNDS | SHIRE LLC (US) | 2012-02-15 | — | — | EP | disclosed |
| CN-1925865-B | Pharmaceutical compositions for prevention of overdose or abuse | SHIRE LLC | 2011-09-14 | — | — | CN | disclosed |
| US-20110009669-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2011-01-13 | — | — | US | disclosed |
| US-20100197798-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2010-08-05 | — | — | US | disclosed |
| US-7723305-B2 | Abuse-resistant amphetamine prodrugs | SHIRE LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-7718619-B2 | Abuse-resistant amphetamine prodrugs | SHIRE LLC (US) | 2010-05-18 | — | — | US | disclosed |
| US-7713936-B2 | Abuse-resistant amphetamine prodrugs | SHIRE LLC (US) | 2010-05-11 | — | — | US | disclosed |
| CN-1816346-A | Abuse resistant amphetamine compounds | NEW RIVER PHARMACEUTICALS INC (US) | 2006-08-09 | — | — | CN | disclosed |
| EP-1675555-A2 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION OF OVERDOSE OR ABUSE | New River Pharmaceuticals Inc. (US) | 2006-07-05 | — | — | EP | disclosed |
| WO-2006052880-A2 | SYNERGISTIC EFFECTS OF COMBINED ADMINISTRATION OF MIRTAZAPINE AND A STIMULANT COMPOUND | NEW RIVER PHARMACEUTICALS INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| US-20060100136-A1 | Synergistic effects of combined administration of mirtazapine and a stimulant compound | SHIRE LLC | 2006-05-11 | — | — | US | disclosed |
| EP-1644019-A1 | ABUSE RESISTANT AMPHETAMINE COMPOUNDS | New River Pharmaceuticals Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20050176646-A1 | Covalently bonding a narcotic to a single amino acid or an oligopeptide of 15 or fewer amino acids such that the narcotic does not release into a patient's bloodstream at levels that give rise to a euphoric or overdose level | NEW RIVER PHARMACEUTICALS INC. (US) | 2005-08-11 | — | — | US | disclosed |
| WO-2005032474-A2 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION OF OVERDOSE OR ABUSE | NEW RIVER PHARMACEUTICALS INC. (US) | 2005-04-14 | — | — | WO | disclosed |
| US-20050054561-A1 | Abuse-resistant amphetamine compounds | NEW RIVER PHARMACEUTICALS INC. | 2005-03-10 | — | — | US | disclosed |
| US-20050038121-A1 | Abuse resistant lysine amphetamine compounds | NEW RIVER PHARMACEUTICALS INC. (US) | 2005-02-17 | — | — | US | disclosed |
| WO-2005000334-A1 | ABUSE RESISTANT AMPHETAMINE COMPOUNDS | NEW RIVER PHARMACEUTICALS, INC. (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054561-A1 | Abuse-resistant amphetamine compounds | COMT, CYP3A5, SLC6A2 | SLC6A2 3/4885SLC6A3 4/4885SLC7A5 617/4885 |
| US-20050038121-A1 | Abuse resistant lysine amphetamine compounds | COMT, KDM6B, KDM5B | SLC6A2 31/4885SLC6A3 33/4885SLC7A5 239/4885 |
| US-20120115950-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | SLC6A2 7/4885SLC6A3 8/4885SLC7A5 733/4885 |
| US-20100197798-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | SLC6A2 7/4885SLC6A3 8/4885SLC7A5 733/4885 |
| US-20050176646-A1 | Covalently bonding a narcotic to a single amino acid or an oligopeptide of 15 or fewer amino acids such that the narcotic does not release into a patient's bloodstream at levels that give rise to a euphoric or overdose level | DNPEP, OGFR, OPRL1 | SLC6A2 54/4885SLC6A3 79/4885SLC7A5 106/4885 |
| US-20060100136-A1 | Synergistic effects of combined administration of mirtazapine and a stimulant compound | SLC6A4, HTR5A, HTR4 | SLC6A2 4/4885SLC6A3 6/4885SLC7A5 671/4885 |
| US-20110009669-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | SLC6A2 7/4885SLC6A3 8/4885SLC7A5 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.